4. For an epinephrine auto-injector prescribed under s. 118.2925 (3) or 255.07 (2), Stats., the name of the school, authorized entity, or other person specified under s. 255.07 (3), Stats. 5. If the patient is an animal, the last name of the owner, name of the animal and animal species.
(b) Symptom or purpose for which the drug is being prescribed if the prescription order specifies the symptom or purpose.
(c) Name and strength of the prescribed drug product or device dispensed, unless the prescribing practitioner requests omission of the name and strength of the drug product or device.
(d) The date for which the medication shall not be used after.
(e) Pharmacy name, address and telephone.
(f) Prescriber name.
(g) Date the prescription was filled.
(h) Prescription order number.
(i) Quantity.
(j) Number of refills or quantity remaining.
(k) Written or graphic product descriptions.
(3) A label for prescribed drugs or devices may include the following:
(a) Symptom or purpose for which the drug is being prescribed if requested by the patient.
(b) Both the generic name of the drug product equivalent and the brand name specified in the prescription order may be listed on the label if the brand name is listed on the prescription and the drug product equivalent is dispensed, unless the prescribing practitioner requests that the brand name be omitted from the label.
(c) Any cautions or other provisions.
(4) Sub. (2) does not apply to complimentary samples of drug products or devices dispensed in original packaging by a practitioner to his or her patients.
Phar 7.06 Repackaging for stock. A pharmacy repackaging for stock any non-sterile drugs shall do all of the following:
(1) The repackaging for stock process is conducted under conditions that ensure the integrity of the drug.
(2) Products repackaged for stock shall include a beyond use date that ensures the integrity of the drug.
(3) The repackaged container shall be selected to mitigate adulteration from light, temperature and humidity.
(4) The repackaged for stock drugs are labeled with all the following components:
(a) Drug name, strength and form.
(b) Pharmacy control or manufacturer lot number.
(c) NDC number. If NDC number is unavailable the name of the manufacturer or distributor of the drug product.
(d) Beyond use date.
(5) Records of all repackaging for stock operations are maintained and include all the following:
(a) Name, strength, form, quantity per container, and quantity of containers.
(b) NDC number. If NDC number is unavailable the name of the manufacturer or distributor of the drug product.
(c) Manufacturer lot number.
(d) Original container’s expiration date and the beyond-use date for the new containers.
(e) First and last name of the pharmacist or delegate that repackaged the drug and the first and last name of the pharmacist that verified the accuracy of the repackaging.
(f) Date of repackaging.
Phar 7.07 Final check (1) The final check on the accuracy and correctness of the prescription drug product or device dispensing includes all of the following:
(a) Labeling requirements.
(b) Correct drug product or device.
(c) Completion of the drug utilization review.
(2) For all prescription drug product or device dispensing, the prescription record shall identify the pharmacist responsible for each part of the final check. If sub. (1) (a) or (b) is completed by delegate check delegate under s. Phar 7.14 or automated technology under s. Phar 7.55, the prescription record shall identify the supervising pharmacist. Phar 7.08 Patient consultation. (1) Patient consultation shall include all of the following:
(a) Name and description of the drug.
(b) Form, dose, route of administration and duration for drug therapy.
(c) Intended use of the drug and expected action.
(d) Special directions and precautions for preparation, administration and use by the patient.
(e) Common severe side or adverse effects or interactions and therapeutic contraindications that may be encountered, including their avoidance, and the action required if they occur.
(f) Techniques for self-monitoring drug therapy.
(g) Proper storage and appropriate disposal method of unwanted or unused medication.
(h) Action to be taken in the event of a missed dose.
(2) A pharmacist shall give the patient or patient’s agent consultation relative to the prescription for any new drug product or device which has not been dispensed previously to the patient or any change in the patient’s therapy. Patient consultation shall meet all of the following requirements:
(a) Contain all of the following information, unless in the pharmacist’s professional judgment it serves the best interest of the patient to omit or vary the content of the consultation:
1. Name and description of the drug.
2. Form, dose, route of administration and duration for drug therapy.
3. Intended use of the drug and expected action.
4. Special directions and precautions for preparation, administration and use by the patient.
5. Common severe side or adverse effects or interactions and therapeutic contraindications that may be encountered, including their avoidance, and the action required if they occur.
6. Techniques for self-monitoring drug therapy.
7. Proper storage and appropriate disposal method of unwanted or unused medication.
8. Action to be taken in the event of a missed dose.
(b) Be communicated orally unless in the pharmacist’s professional judgment it is not in the best interest of the patient or patient’s agent to be communicated orally.
(c) Provide written documentation of the information in par. (a) 1. to 8.
(d) Advise the patient or patient’s agent the method which the pharmacist may be contacted for consultation.
(3) The consultation requirement is not satisfied by only offering to provide consultation.
(4) Every licensed pharmacy directly serving patients at a physical location must conspicuously post a sign approved by the board stating a patient’s rights to consultation and information on how to file a complaint to the Board for failure to consult. A copy of the sign must be included in any delivery by common carrier or delivery service.
(5) Consultation is required upon patient request.
(6) A pharmacist shall utilize professional judgement in determining whether to give the patient or patient’s agent appropriate consultation relative to the prescription for any refill.
(7) Notwithstanding sub. (2), a consultation is not required when a health care provider is administering the medication or if a patient or patient’s agent refuses consultation.
Phar 7.085 Delivery by common carrier or delivery services. Utilization of common carrier or delivery services to deliver a prescription from the pharmacy which fills the prescription to the patient or patient’s agent shall ensure all of the following:
(1) The delivery method maintains appropriate environmental controls, including temperature and humidity, to prevent drug adulteration.
(2) The delivery method provides for verification of receipt of all controlled substances.
(3) The patient or patient’s agent is provided a method by which the patient or patient’s agent can notify the pharmacy as to any irregularity in the delivery of the prescription drug product or device, including all of the following:
(a) Timeliness of delivery.
(b) Condition of the prescription drug upon delivery.
(c) Failure to receive the proper prescription drug product or device.
(4) Any prescription drug product or device which is compromised by delivery shall be replaced by the pharmacy. The pharmacy shall replace at no additional cost to the patient the prescription drug product or device by next-day delivery or the pharmacist shall contact the patient’s practitioner to arrange for a prescription for a minimum 7 day supply of the prescription drug product to be dispensed to the patient by a pharmacy of the patient’s choice.
Phar 7.09 Procurement, recall and out-of-date drugs and devices.
(1) Procurement of prescription drugs and devices shall be from a drug wholesaler licensed by the board or U.S. food and drug administration to distribute to pharmacies or from another licensed pharmacy or licensed practitioner located in the United States.
(2) A pharmacy shall have a system for identifying any drugs or devices subjected to a product recall and for taking appropriate actions as required by the recall notice.
(3) Any drug or device may not be dispensed after the drug’s or device’s expiration date or beyond use date. Outdated drugs or devices shall be removed from dispensing stock and shall be quarantined until such drugs or devices are properly disposed.
7.10 Return or exchange of health items. (1) In this section:
(a) “Health item” means drugs, devices, hypodermic syringes, needles or other objects for injecting a drug product, or items of personal hygiene.
(b) “Original container” means the container in which a health item was sold, distributed, or dispensed.
(c) “Tamper-evident package” means a package that has one or more indicators or barriers to entry which, if breached or missing, can reasonably be expected to provide visible evidence that tampering has occurred.
(2) No health item after taken from a pharmacy where sold, distributed or dispensed, may be returned to that pharmacy, except for any of the following:
(a) Where the health item was dispensed in error, was defective, adulterated, or misbranded.
